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Abstract
Burkholderia is a bacterial genus comprising several pathogenic species, including two species highly pathogenic for
humans, B. pseudomallei and B. mallei. B. thailandensis is a weakly pathogenic species closely related to both B. pseudomallei
and B. mallei. It is used as a study model. These bacteria are able to exhibit multiple resistance mechanisms towards various
families of antibiotics. By sequentially plating B. thailandensis wild type strains on chloramphenicol we obtained several
resistant variants. This chloramphenicol-induced resistance was associated with resistance against structurally unrelated
antibiotics including quinolones and tetracyclines. We functionally and proteomically demonstrate that this multidrug
resistance phenotype, identified in chloramphenicol-resistant variants, is associated with the overexpression of two different
efflux pumps. These efflux pumps are able to expel antibiotics from several families, including chloramphenicol, quinolones,
tetracyclines, trimethoprim and some b-lactams, and present a partial susceptibility to efflux pump inhibitors. It is thus
possible that Burkholderia species can develop such adaptive resistance mechanisms in response to antibiotic pressure
resulting in emergence of multidrug resistant strains. Antibiotics known to easily induce overexpression of these efflux
pumps should be used with discernment in the treatment of Burkholderia infections.
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Introduction
Burkholderia thailandensis is an environmental bacterial species
which is considered to be an opportunist pathogen [1]. There are
only few documented cases of infectious diseases in human
associated with this Gram-negative bacterium and they generally
involve immunocompromized patients already suffering from
other diseases [2], for example cystic fibrosis (unpublished data).
The genome of B. thailandensis shows extensive similarities with the
genomes of B. pseudomallei, the causative agent of melioidosis and of
B. mallei, the etiological agent of glanders [3,4]. The treatments of
these infections are both cumbersome and prolonged, and involve
the administration of multiple antibiotics [5,6]. These bacterial
species express several resistance mechanisms leading to a
decreased sensitivity to many antibiotics [7,8]. Furthermore, there
are cases of emergence of resistant isolates during treatment in
patient with relapse with the same strain that it can generate
therapeutic failures [9,10]. The best described resistance mecha-
nisms in this bacterial genus are b-lactamases and Multi Drug
Resistance (MDR) efflux pumps [11]. B. thailandensis, biochemically
and genetically closely related to B. pseudomallei and to B. mallei,i sa
useful model system for studying the resistance mechanisms in
Burkholderia spp. [4,12]. Interestingly, the B. thailandensis genome
contains many putative Resistance Nodulation cell Division
(RND) efflux pump genes closely related to those of B. pseudomallei
[4]. Four efflux pumps involved in the active extrusion of drugs
have been identified in B. pseudomallei: AmrAB-OprA, BpeAB-
OprB, BpeEF-OprC, BpeGH-OprD [13,14,15,16,17,18], al-
though, only the first three of these have been demonstrated to
be associated with antibiotic resistance. There are also many
additional putative RND efflux pumps in this species, but which
have not been characterized in resistant strains [4,19]. However,
none of efflux pump has been yet described in B. thailandensis.
The aim of this work was to investigate the adaptive response of
B. thailandensis in medium containing chloramphenicol and to
characterize the expression of the corresponding resistance
mechanisms. We used a proteomic method to assess the
involvement of RND efflux pumps in the antibiotic resistances
expressed by B. thailandensis. Chloramphenicol was chosen because
we have previously demonstrated that this antibiotic is able to
select in vitro resistant strains of Gram-negative bacteria that
overproduce the AcrAB pump, a major efflux pump in clinical
isolates of Enterobacteriaceae [20,21]. Furthermore, chloramphenicol
has been used for a long time as first intention treatment and can
be still used in particular cases of melioidosis [5,8]. To investigate
chloramphenicol as an activator of the multidrug resistance
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coli and Enterobacter aerogenes [22,23], resistant variants were
obtained by cultivating a susceptible strain of B. thailandensis in
the presence of increasing chloramphenicol concentrations.
The resulting variants exhibited decreased susceptibility not
only to chloramphenicol but also to other chemically unrelated
antibiotics. We studied the genetic and proteomic characteristics of
these strains to assess the involvement of efflux pumps in the
multidrug resistance.
Results
Antibiotic susceptibility of B. thailandensis variants
B. thailandensis strains ATCC 700388 and PHLSE082 were
grown in the presence of chloramphenicol (4–128 mg/mL) and
successive chloramphenicol-resistant derivatives were isolated. We
kept only four derivatives for each strain: 64CM16, 64CM32,
64CM64 and 64CM128 from the wild-type strain ATCC 700388,
which were respectively grown at a concentration of 16, 32, 64 and
128 mg/mL; and 132CM16, 132CM32, 132CM64 and
132CM128 from the wild-type strain PHLSE082. The MICs of
various antibiotics for these strains were determined and
compared with those for the parental susceptible strains (Table 1).
The resistant variants from the two wild-type strains ATCC
700388 and PHLSE082 exhibited significant decreases of
susceptibility not only to the chloramphenicol but to other
structurally-unrelated antibiotics including quinolones, fluoroquin-
olones, trimethoprim, trimethoprim-sulfamethoxazole, and the b-
lactams oxacillin and cloxacillin, and doxycycline (Table 1 and
data not shown). By contrast, the MICs for erythromycin,
ceftazidime, imipenem and piperacillin for the variants did not
differ substantially from those of the parental strains. Specific
mechanisms, such as target mutation or enzymatic modification of
drugs, can only confer cross resistance within single antibiotic
families. The decrease of susceptibility to antibiotics of different
classes —chloramphenicol, quinolones, cyclines, trimethoprim,
some b-lactams— therefore suggests that the resistant strains
express a non-specific resistance mechanism, such as membrane
modification or efflux pump overexpression. The MICs of
imipenem, ceftazidime or piperacillin are not affected in the
chloramphenicol resistant strains. These molecules use the porin
way to penetrate the outer membrane [24] and this suggests that
porin alterations are not involved in the induced multidrug
resistance. In order to assess a possible modification of the outer
leaflet constituted by the lipopolysaccharide (LPS), we tested
various EDTA concentrations (1 and 2 mmol/L) during MIC
determination. It has been previously observed that the addition of
chelators such as EDTA is able to induce decrease of MICs
[25,26]. The susceptibilities to chloramphenicol, polymyxin B and
nalidixic acid were not increased in the presence of EDTA in the
chloramphenicol resistant strains (data not shown). This suggests
that, in the various chloramphenicol resistant strains, the
modification of the bacterial susceptibility to tested antibiotic
molecules cannot be associated with a LPS modification including
drastic changes in structure and charges [27].
Effect of efflux pump inhibitors on antibiotic
susceptibility
To assess the involvement of an active efflux of antibiotics, we
compared the MICs for chloramphenicol-resistant strains in the
presence and absence of two well-characterized efflux pump
inhibitors (EPI), PAbN and verapamil, and also of the quinazoline
derivative 1190 [28]. For all strains, MICs of PAbN and
quinazoline derivative 1190 were greater than 2048 mg/mL and
MICs of verapamil were greater than or equal to 512 mg/mL (data
not shown). We tested whether various different sub-inhibitory
concentrations of the three EPIs restored antibiotic activity. The
presence of PAbN partially restored the antibiotic activity of
chloramphenicol, nalidixic acid and cloxacillin: at about 1/10
th of
its MIC for efflux, PAbN reduced the MICs of these three
structurally-unrelated molecules by about 2-4-fold (Table 2). Note
that cloxacillin is a substrate of efflux pumps and its efflux is
decreased by the presence of PAbN [28,29]. Quinazoline
derivative 1190 reduced the MICs of chloramphenicol by about
2-4-fold whereas verapamil, an inhibitor of ABC drug transport-
ers, had no significant effect, even at high concentrations, on
chloramphenicol susceptibility (data not shown).
SDS-PAGE analysis of membrane fractions from the
various B. thailandensis strains
The proteins present in the detergent-insoluble membrane
fractions obtained from the various resistant and parental strains
were analyzed by SDS-polyacrylamide gel electrophoresis
(Figure 1). Protein staining revealed differences in the intensities
of some bands between the variants and the wild-type strains.
Proteins migrating at around 51 kDa (band A), 48 kDa (band B),
43 kDa (band C and band E) and at 95 kDa (band D) seemed to
be more abundant in the membrane fractions derived from the
resistant variants than those from the parental strains. These
differences in band intensities were reproducibly observed in
several independent SDS-PAGE analyses. The corresponding
proteins, excised from gels, were identified by mass spectrometry.
Due to the strong interactions between the components of efflux
Table 1. Antibiotic susceptibility of the B. thailandensis strains.
B. thailandensis strains MIC (mg/mL)
CM NAL NFX CIP FOX CAZ OXA CLO PIP IMI ERY TC DC TP TS POL B
ATCC 700388 8/16 32 16 4 1024 4 128/256 256 4/8 0.19 256 6 2 8 0.75 .2048
64CM16 128/256 256 64/128 16 .4096 2 1024 1024 8/16 0.19 512 12 8 .32 1 .2048
64CM32 256 256 64/128 16 .4096 4 1024 1024 8 0.19 512 12 12 .32 1.5 .2048
64CM64 256 256/512 64/128 16 .4096 2 1024 2048 8 0.25 512 24 24 .32 .32 .2048
64CM128 512 512 128 32 .4096 2 1024 1024 8 0.125 512 12 12 .32 4 .2048
Antimicrobial agent abbreviations: CM, chloramphenicol; NAL, nalidixic acid; NFX, norfloxacin; CIP, ciprofloxacin; FOX, cefoxitin; CAZ, ceftazidime; OXA, oxacillin; CLO,
cloxacillin; PIP, piperacillin; IMI, imipenem; ERY, erythromycin; TC, tetracycline; DC, doxycycline; TP, trimethoprim; TS, trimethoprim/sulfamethoxazole; POL B, polymyxin
B. Values are means of three independent determinations.
doi:10.1371/journal.pone.0016892.t001
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pump), we observed a ‘‘co-fractionation’’ of the different
membrane proteins during the detergent extraction.
Identification of drug efflux pumps overproduced in the
resistant variants
Various bands (A, B, C, D and E), absent or weakly expressed
in the wild-type and more abundant in resistant strains, were
excised from the gels; the proteins were retrieved and used for
mass spectrometry determinations. The mass spectrum of band
A (51 kDa) matched against the NCBR (Genbank) bank was
identified as BTH_I0682 (54,799 Da) an outer membrane
channel reported in Burkholderia thailandensis strain E264 [3].
This outer membrane channel of the RND efflux pump
presented 99% identity with a putative protein named
BTH_II1286. A homologous protein (99%) named OprB of
Table 2. Effects of PAbN on antibiotic susceptibility of the B. thailandensis strains.
MIC (mg/mL)
CM NAL CLO
PAbN( mg/mL) PAbN( mg/mL) PAbN( mg/mL)
strains 0 20 50 80 100 200 0 20 50 80 100 200 0 50 100 200
ATCC 700388 16 16 16 16 8 8 32 32 32 32 16 16 256 64 64 32
64CM32 256 256 256 128 128 64 256 256 256 128 128 64 1024 256 128 64
64CM128 512 512 512 512 512 128 512 512 512 256 128 64 1024 512 512 256
Abbreviations: PAbN, phenylalanine-arginine b-naphthylamide; CM, chloramphenicol; NAL, nalidixic acid; CLO, cloxacillin.
doi:10.1371/journal.pone.0016892.t002
Figure 1. Analyses of the detergent-insoluble membrane proteins of chloramphenicol-resistant variants. SDS-PAGE analysis was
performed on ATCC700388 and PHLSE082, two wild-type strains of B. thailandensis, and on 64CM16 and 132CM128, their respectively
chloramphenicol resistant derivative strains. Proteins were stained with Coomassie blue. The variants presented different additional bands at around
51 kDa (band A), 48 kDa (band B), 43 kDa (bands C and band E) and at 95 kDa (band D). Molecular weight standards are indicated in kilodaltons.
doi:10.1371/journal.pone.0016892.g001
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corresponds to the outer membrane channel of the RND efflux
pump BpeAB-OprB [13]. In Pseudomonas aeruginosa PA01, the
homologue of BTH_I0682 is OprM (56% amino acid sequence
identity) (Table 3) [30].
The bands C and E (43 kDa) were identified as the same
protein, another component of RND efflux pump: the Major
Facilitator Protein (MFP) subunit, periplasmic adaptator or
membrane fusion protein. The name of the corresponding locus
is BTH_I0680 (43,086 Da). This subunit is the homologue of
BpeA of B. pseudomallei and MexA of P. aeruginosa (Table 3) [30].
Band D (93 kDa) was identified as BTH_I0681 (114,571 Da)
which is a putative pump homologue of BpeB of B. pseudomallei and
MexB of P. aeruginosa [30].
Band B (48 kDa) was identified as BTH_II2104 (54,869 Da).
This protein is the homologue of OprC in B. pseudomallei. OprC
has been described to be the outer membrane channel of the RND
efflux pump BpeEF-OprC [14]. No homologous putative protein
was found in the P. aeruginosa PA01 genome.
These related proteins were more abundant in the membrane
fraction of the resistant strain than parental strains. Similar
overproduction of these membrane proteins was found in strains
selected by chloramphenicol from the both wild-type strains (data
not shown). Presumably, the RND efflux pumps identified as being
overproduced in the chloramphenicol-resistant variants are
involved in the MDR phenotype.
Discussion
B. thailandensis is a Gram-negative bacterium which can cause
infections in patients with other underlying disease such as
immunocompromized state. Our aim was to study the B.
thailandensis response to chloramphenicol, an antibiotic able to
induce efflux in Enterobacteriae. Resistant variants were isolated by
culture in presence of increasing chloramphenicol concentrations,
as previously used for selection of antibiotic-resistant E. aerogenes
strains [31]. By using low concentrations of antibiotics, our
objective was to make the two strains, ATCC 700388 and
PHLSE082, to become progressively more resistant to chloram-
phenicol, in a process we call ‘‘training’’. We tested the MICs of
various antibiotics for these variants, and found a significant
decrease of susceptibility not only for the chloramphenicol, but
also for other, structurally-unrelated, antibiotic families, and in
particular quinolones, fluoroquinolones, tetracyclines, trimetho-
prim-sulfamethoxazole and some b-lactams. The MDR phenotype
of these variants suggests the presence of a non-specific drug
resistance mechanism, such as the decrease of antibiotic influx or
the overexpression of efflux pumps, or both. Indeed, these
mechanisms together constitute the bacterial mechanical barrier
to antibiotics [24] and MDR mechanisms of this type have been
described in other Gram-negative bacteria, notably Enterobacteri-
aceae and the more closely related P. aeruginosa [32].
To assess the possible involvement of efflux mechanisms in our
selected MDR strains, we investigated the effect of efflux pump
inhibitors on their susceptibility to antibiotics. Susceptibility to
chloramphenicol, quinolones and cloxacillin was partially restored
by the presence of PAbN, an inhibitor of RND efflux pumps, but
not by the presence of verapamil, an inhibitor of ABC transporter
[28]. A similar effect was obtained with compound 1190, a
quinazoline derivative recently reported to restore partial
susceptibility in E. aerogenes, Klebsiella pneumoniae and P. aeruginosa
MDR isolates that overexpress AcrAB-TolC or MexAB-OprM
efflux pumps [33]. These results suggest that the expression of an
RND efflux pump, sensitive to efflux pump inhibitor, contributes
to the resistance of these strains to chloramphenicol, nalidixic acid
and cloxacillin. As the susceptibilities to these antibiotics are not
totally restored even by using high concentrations of PAbN, we
could not exclude the presence in B. thailandensis of additional
mechanisms such as membrane modification or the expression of
another efflux pump which would be unsusceptible to PAbN [13].
However it must be noted that the susceptibilities of imipenem,
ceftazidime or piperacillin were not affected in the chloramphen-
icol resistant strains. This result suggests that the membrane
permeability, regarding porins or membrane fluidity, could not be
involved in the resistance level obtained in resistant strains [22].
Furthermore, we have observed no modification of the suscepti-
bility to chloramphenicol, polymyxin B and nalidixic acid during
the addition of the chelator EDTA that affects the LPS [27].
Consequently, the modification of LPS structure seems not
involved in the multidrug resistance phenotype of our chloram-
phenicol resistant variants.
We investigated membrane proteins of the variants by 1-D
SDS-PAGE combined with protein identification by trypsin
digestion and MS analysis (Table 3). This analysis indicated that
all the resistant variants selected by chloramphenicol overpro-
duced at least one RND efflux pump homologous to BpeAB-
OprB in B. pseudomallei and encoded by the operon bth_I0680-
bth_I0681-bth_I0682 on chromosome I of B. thailandensis.O u r
results are in accordance with those of Mima et al. who
demonstrated that the homologue of BTH_I0680-BTH_I0681-
Table 3. Identification of two drug efflux pumps overproduced in the resistant variants.
Band
no. Assession no. Protein Mol. wt. (Da)
Protein
score % coverage
Peptide
(Hits)
Homologues in
B. pseudomallei
1106b
Homologues in
P. aeruginosa PAO1
A GI|257142607 BTH_I0682
BTH_II1286
54,799
57,702
130.24 26.51 57 OprB
99% identities
OprM
56% identities
B GI|257140923 BTH_II2104 54,869 100.17 25.49 12 OprC
99% identities
No homologous
protein
C GI|257140098 BTH_I0680 43,086 160.22 45.99 45 BpeA
99% identities
MexA
53% identities
D GI|257140097 BTH_I0681 114,571 250.19 21.48 69 BpeB
99% identities
MexB
64% identities
E GI|257140098 BTH_I0680 43,086 140.28 46.52 50 BpeA
99% identities
MexA
53% identities
doi:10.1371/journal.pone.0016892.t003
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phenicol, tetracyclines and fluoroquinolones [15]. Furthermore,
the antibiotics substrates of BTH_I0680-BTH_I0681-
BTH_I0682 are the same of its homologue MexAB-OprM in
P. aeruginosa [30,34].
The presence of chloramphenicol favors the overexpression of
BpeAB-OprB homologue in B. thailandensis as previously described
for AcrAB-TolC in E. aerogenes [22]. It is likely that chloramphen-
icol is a well-recognized substrate and may act as selector for this
pump expression.
However, we detected a component of another efflux pump, the
outer membrane channel BTH_II2104 of the RND efflux pump
BTH_II2104-BTH_II2105-BTH_II2106. This efflux pump is
homologous to the BpeEF-OprC of B. pseudomallei 1106b [14].
BpeEF-OprC has been proposed to expel antibiotics including
chloramphenicol, tetracyclines and trimethoprim [14,35]. Over-
expression of this pump may thus explain the increased MICs of
chloramphenicol and trimethoprim observed for our variants. We
observed overproduction of the homologue of OprC in one
resistant variant (132CM128), a variant growing on the media
containing the highest concentration of chloramphenicol, whereas
the homologue of BpeAB-OprB was overproduced in all
chloramphenicol-resistant variants. Possibly, the homologue of
BpeAB-OprB is overexpressed before the homologue of BpeEF-
OprC under chloramphenicol stress; the latter only being
expressed under high concentrations of chloramphenicol.
We only found the outer membrane channel of this pump and
not the other components homologous to BpeEF. Either SDS-
PAGE analysis failed to reveal the other components of the
original pump associated with BTH_II2104, or alternatively
BTH_II2104 may be associated with the BpeAB homologue.
Indeed, such functional combinations between components of
different RND efflux pumps have been demonstrated in P.
aeruginosa [36]. These associations between components of different
RND efflux pumps may modulate the affinities of these
transporters for different substrates.
We did not construct any mutants deleted in the two identified
efflux pumps because it has been demonstrated that another
pump could be overexpressed in order to compensate the lacking
pump [37]. In our case, we can observe that at least two pumps
are able to be sequentially overexpressed for maintaining the
survival of the bacteria under high level concentrations of
chloramphenicol.
Interestingly, susceptibility to imipenem, ceftazidime and
piperacillin was preserved in the MDR variants we obtained.
Possibly, the efflux pumps activated in B. thailandensis by
chloramphenicol do not have affinity for these antibiotics.
Vitkorov et al. [18] have recently shown that growing B.
thailandensis and B. pseudomallei on media containing ceftazidime
and fluoroquinolones was possible and could generate MDR with
a profile similar to that we describe here in B. thailandensis.
In conclusion, these data demonstrated that B. thailandensis is
able to adapt to antibiotic stress by using diverse coordinated efflux
pumps. This indicates that the choice of appropriate antibiotics is
essential for treatment success of Burkholderia infections. As a
consequence, the bacterial adaptation to chloramphenicol and the
resulting MDR we report lead us to conclude that it is possible that
one antibiotic is able to generate a resistance to the main antibiotic
families included to the oral phase of treatment of Burkholderia
infections. It could be of interest to lead similar studies in more
pathogenic species of Burkholderia as B. pseudomallei and B. mallei and
explore the role of active efflux induced by the treatment in the
cases of relapses in melioidosis and glanders.
Materials and Methods
Bacterial strains, growth media and selection of
chloramphenicol-resistant strains
Bacteria were grown at 37uC in Luria–Bertani (LB) broth, in
Trypticase soya (TS) broth or in TS agar media (Difco
Laboratories, Detroit, MI, USA). B. thailandensis ATCC 700388
(type strain) was used as the wild-type strain. Four strains named
64CM16, 64CM32, 64CM64 and 64CM128 were sequentially
obtained from the reference strain ATCC 700388 by growing on a
gradient with concentration steps of 8–16, 16–32, 32–64, and 64–
128 mg/mL chloramphenicol. The resulting strains, ATCC
700388, 64CM16, 64CM32, 64CM64 and 64CM128, were
routinely maintained with respectively 0, 16, 32, 64 and
128 mg/mL of chloramphenicol. The same method was used for
another strain of B. thailandensis named PHLSE082 (HPA, UK,
formerly PHLS) to generate four chloramphenicol-resistant
variants named, respectively, 132CM16, 132CM32, 132CM64
and 132CM128.
Antibiotic susceptibility tests
Minimal Inhibitory Concentrations (MIC) of chloramphenicol,
nalidixic acid, ciprofloxacin, norfloxacin, cefoxitin, oxacillin,
cloxacillin, piperacillin, erythromycin, imipenem and polymyxin
B (Merck Sharp Dohme and Chibret, Paris, France; Bristol-Myers
Squibb, Paris, France; and Sigma-Aldrich, MO, USA) were
measured by the broth dilution method, as previously described
[38] and according to the Clinical and Laboratory Standards
Institute (http://www.clsi.org – October 2010) and the Comite ´d e
l’Antibiogramme de la Socie ´te ´ Franc ¸aise de Microbiologie (http://
www.sfm.asso.fr/publi/general.php?pa=1 – October 2010). Ap-
proximately 10
6 cells were used to inoculate 1 mL Mueller Hinton
II broth (Becton Dickinson and Company, Sparks, MD, USA)
containing twofold serial dilutions of each antibiotic. Results were
read after incubation for 24 h at 37uC and are expressed as MICs
in mg/mL. MICs of tetracycline, doxycycline, trimethoprim and
trimethoprim-sulfamethoxazole and imipenem were measured by
the EtestH method (Biome ´rieux). The efflux pump inhibitors,
phenylalanine-arginine b-naphthylamide (PAbN), verapamil (Sig-
ma-Aldrich, MO, USA) and a quinazoline derivative, named
1190, synthesized by our drug design laboratory, were used as
previously described [39]. These efflux pumps inhibitors (PAbN,
from 20 to 200 mg/L; verapamil, 50 and 100 mg/L; quinazoline
derivative 1190, 162, 325 and 650 mg/L) are incorporated in the
broth containing the cells so that to obtain the final given
concentration. EDTA (Sigma-Aldrich, MO, USA) was used at
different concentrations (1 and 2 mmol/L) in association with
chloramphenicol, nalidixic acid and polymyxin B.
Preparation of membrane fractions
Bacterial membrane fractions were prepared from 50 mL mid-
exponential phase cultures. Bacteria were harvested, washed, and
resuspended in 10 mL cold sodium phosphate buffer (100 mM
NaH2PO4/Na2HPO4, pH 7.4) containing 1 mg/mL lysosyme.
Cells were lysed by sonication (Branson Sonifier 450; 50% duty
cycle; amplitude setting 20%; total time 7 min) and unbroken
bacteria were removed by centrifugation (5,000 g; 20 min; 4uC).
Whole membranes were recovered from the supernatant by
ultracentrifugation (40,000 g; 60 min; 4uC) and incubated in
0.15% sodium N-laurylsarcosinate for 30 min at room tempera-
ture to extract the detergent-soluble material modified from the
previously described procedure [22]. The insoluble membrane
fractions were pelleted by centrifugation (40,000 g; 60 min; 20uC).
Efflux Pump Expression in B. thailandensis
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and heated for 5 min at 95uC as previously described [31].
SDS-PAGE
Exponential growing bacteria in LB broth were pelleted and
solubilised in boiling buffer at 95uC as described elsewhere [31].
Samples were loaded onto SDS-polyacrylamide gels (10%
polyacrylamide, 0.1% SDS). After migration, gels were stained
with Coomassie Brillant Blue R-250.
Protein identification: peptides digestion and nano
electrospray MS/MS identification
Protein bands were excised from gels and digested in the
resulting gel plugs with sequencing grade modified porcine trypsin
(12.5 ng/L, Promega, Madison, WI). The peptides were extracted,
dried in a vacuum, centrifuged, and redissolved in 10 to 20 mLo f
0.1% trifluoroacetic acid.
For Nano electrospray MS/MS identification, mass spectro-
metric measurements were done on a LCQTM Deca XP Plus ion
trap mass spectrometer (ThermoFinnigan) equipped with a
LCQTM nanospray ionization source. Digested peptides were
separated using an Ettan MDLC chromatographic system (GE
Healthcare) piloted by Unicorn 5.01 software (GE Healthcare).
Three dependent MS/MS spectra of the three most intense peaks
were collected following one full scan mass spectrum. Extracted
MS/MS spectra were automatically assigned by the Mascot
software to the best matching peptide sequence in the NCBI non
redundant Database. The identifications were checked by using
various peptides obtained by digestion.
Acknowledgments
We thank D. Lafitte for fruitful discussions, and S. Lignon, R. Lebrun and
A. Caclard for helpful technical assistance.
Author Contributions
Conceived and designed the experiments: FVB EV J-MP. Performed the
experiments: FVB EV JC J-MP. Analyzed the data: FVB EV EG FMT J-
MP. Contributed reagents/materials/analysis tools: FVB EV EG JC CV
DRV J-MP. Wrote the paper: FVB EV FMT DRV J-MP.
References
1. Brett PJ, DeShazer D, Woods DE (1998) Burkholderia thailandensis sp. nov., a
Burkholderia pseudomallei-like species. Int J Syst Bacteriol 48(Pt 1): 317–320.
2. Glass MB, Gee JE, Steigerwalt AG, Cavuoti D, Barton T, et al. (2006)
Pneumonia and septicemia caused by Burkholderia thailandensis in the United
States. J Clin Microbiol 44: 4601–4604.
3. Kim HS, Schell MA, Yu Y, Ulrich RL, Sarria SH, et al. (2005) Bacterial genome
adaptation to niches: divergence of the potential virulence genes in three
Burkholderia species of different survival strategies. BMC Genomics 6: 174.
4. Yu Y, Kim HS, Chua HH, Lin CH, Sim SH, et al. (2006) Genomic patterns of
pathogen evolution revealed by comparison of Burkholderia pseudomallei,t h e
causative agent of melioidosis, to avirulent Burkholderia thailandensis. BMC
Microbiol 6: 46.
5. White NJ (2003) Melioidosis. Lancet 361: 1715–1722.
6. Chaowagul W, Chierakul W, Simpson AJ, Short JM, Stepniewska K, et al.
(2005) Open-label randomized trial of oral trimethoprim-sulfamethoxazole,
doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxa-
zole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents
Chemother 49: 4020–4025.
7. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD (2004)
Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia
mallei to 35 antimicrobial agents. J Antimicrob Chemother 54: 1134–1138.
8. Estes DM, Dow SW, Schweizer HP, Torres AG (2010) Present and future
therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther
8: 325–338.
9. Jenney AW, Lum G, Fisher DA, Currie BJ (2001) Antibiotic susceptibility of
Burkholderia pseudomallei from tropical northern Australia and implications for
therapy of melioidosis. Int J Antimicrob Agents 17: 109–113.
10. Dance DA, Wuthiekanun V, Chaowagul W, White NJ (1989) The antimicrobial
susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and
during treatment. J Antimicrob Chemother 24: 295–309.
11. Godfrey AJ, Wong S, Dance DA, Chaowagul W, Bryan LE (1991) Pseudomonas
pseudomallei resistance to beta-lactam antibiotics due to alterations in the
chromosomally encoded beta-lactamase. Antimicrob Agents Chemother 35:
1635–1640.
12. Ong C, Ooi CH, Wang D, Chong H, Ng KC, et al. (2004) Patterns of large-scale
genomic variation in virulent and avirulent Burkholderia species. Genome Res 14:
2295–2307.
13. Chan YY, Tan TM, Ong YM, Chua KL (2004) BpeAB-OprB, a multidrug
efflux pump in Burkholderia pseudomallei. Antimicrob Agents Chemother 48:
1128–1135.
14. Kumar A, Chua KL, Schweizer HP (2006) Method for regulated expression of
single-copy efflux pump genes in a surrogate Pseudomonas aeruginosa strain:
identification of the BpeEF-OprC chloramphenicol and trimethoprim efflux
pump of Burkholderia pseudomallei 1026b. Antimicrob Agents Chemother 50:
3460–3463.
15. Mima T, Schweizer HP (2010) The BpeAB-OprB efflux pump of Burkholderia
pseudomallei 1026b does not play a role in quorum sensing, virulence factor
production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux
system. Antimicrob Agents Chemother 54: 3113–3120.
16. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE (1999) Efflux-
mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei.
Antimicrob Agents Chemother 43: 465–470.
17. Trunck LA, Propst KL, Wuthiekanun V, Tuanyok A, Beckstrom-Sternberg SM,
et al. (2009) Molecular basis of rare aminoglycoside susceptibility and
pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS
Negl Trop Dis 3: e519.
18. Viktorov DV, Zakharova IB, Podshivalova MV, Kalinkina EV, Merinova OA,
et al. (2008) High-level resistance to fluoroquinolones and cephalosporins in
Burkholderia pseudomallei and closely related species. Trans R Soc Trop Med Hyg
102(Suppl 1): S103–110.
19. Thongdee M, Gallagher LA, Schell M, Dharakul T, Songsivilai S, et al. (2008)
Targeted mutagenesis of Burkholderia thailandensis and Burkholderia pseudomallei
through natural transformation of PCR fragments. Appl Environ Microbiol 74:
2985–2989.
20. Okusu H, Ma D, Nikaido H (1996) AcrAB efflux pump plays a major role in the
antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance
(Mar) mutants. J Bacteriol 178: 306–308.
21. Pradel E, Pages JM (2002) The AcrAB-TolC efflux pump contributes to
multidrug resistance in the nosocomial pathogen Enterobacter aerogenes. Antimicrob
Agents Chemother 46: 2640–2643.
22. Ghisalberti D, Masi M, Pages JM, Chevalier J (2005) Chloramphenicol and
expression of multidrug efflux pump in Enterobacter aerogenes. Biochem Biophys
Res Commun 328: 1113–1118.
23. McMurry LM, George AM, Levy SB (1994) Active efflux of chloramphenicol in
susceptible Escherichia coli strains and in multiple-antibiotic-resistant (Mar)
mutants. Antimicrob Agents Chemother 38: 542–546.
24. Davin-Regli A, Bolla JM, James CE, Lavigne JP, Chevalier J, et al. (2008)
Membrane permeability and regulation of drug ‘‘influx and efflux’’ in
enterobacterial pathogens. Curr Drug Targets 9: 750–759.
25. Mamelli L, Petit S, Chevalier J, Giglione C, Lieutaud A, et al. (2009) New
antibiotic molecules: bypassing the membrane barrier of gram negative
bacteria increases the activity of peptide deformylase inhibitors. PLoS One 4:
e6443.
26. Vaara M (1992) Agents that increase the permeability of the outer membrane.
Microbiol Rev 56: 395–411.
27. Nikaido H (2003) Molecular basis of bacterial outer membrane permeability
revisited. Microbiol Mol Biol Rev 67: 593–656.
28. Pages JM, Amaral L (2009) Mechanisms of drug efflux and strategies to combat
them: challenging the efflux pump of Gram-negative bacteria. Biochim Biophys
Acta 1794: 826–833.
29. Pages JM, Lavigne JP, Leflon-Guibout V, Marcon E, Bert F, et al. (2009) Efflux
pump, the masked side of beta-lactam resistance in Klebsiella pneumoniae clinical
isolates. PLoS One 4: e4817.
30. Li XZ, Nikaido H, Poole K (1995) Role of mexA-mexB-oprM in antibiotic efflux
in Pseudomonas aeruginosa. Antimicrob Agents Chemother 39: 1948–1953.
31. Bornet C, Chollet R, Mallea M, Chevalier J, Davin-Regli A, et al. (2003)
Imipenem and expression of multidrug efflux pump in Enterobacter aerogenes.
Biochem Biophys Res Commun 301: 985–990.
32. Poole K (2004) Efflux-mediated multiresistance in Gram-negative bacteria. Clin
Microbiol Infect 10: 12–26.
33. Chevalier J, Mahamoud A, Baitiche M, Adam E, Viveiros M, et al. (2010)
Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in
Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant
strains. Int J Antimicrob Agents 36: 164–168.
34. Schweizer HP (2003) Efflux as a mechanism of resistance to antimicrobials in
Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet Mol
Res 2: 48–62.
Efflux Pump Expression in B. thailandensis
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e1689235. Mima T, Schweizer HP, Xu ZQ (2010) In vitro activity of cethromycin against
Burkholderia pseudomallei and investigation of mechanism of resistance.
J Antimicrob Chemother. [Epub ahead of print] 2010 Oct 21.
36. Yoshihara E, Eda S, Kaitou S (2009) Functional interaction sites of OprM with
MexAB in the Pseudomonas aeruginosa multidrug efflux pump. FEMS Microbiol
Lett 299: 200–204.
37. Kumar A, Mayo M, Trunck LA, Cheng AC, Currie BJ, et al. (2008) Expression
of resistance-nodulation-cell-division efflux pumps in commonly used Burkholderia
pseudomallei strains and clinical isolates from northern Australia. Trans R Soc
Trop Med Hyg 102(Suppl 1): S145–151.
38. Mallea M, Chevalier J, Bornet C, Eyraud A, Davin-Regli A, et al. (1998) Porin
alteration and active efflux: two in vivo drug resistance strategies used by
Enterobacter aerogenes. Microbiology 144(Pt 11): 3003–3009.
39. Chevalier J, Bredin J, Mahamoud A, Mallea M, Barbe J, et al. (2004) Inhibitors
of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains.
Antimicrob Agents Chemother 48: 1043–1046.
Efflux Pump Expression in B. thailandensis
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16892